IMR Press / CEOG / Volume 16 / Issue 1 / pii/1634203573156-1555096384

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Mode of delivery and level of passive immunity against herpes simplex virus
Show Less
1 Institute of Microbiology and Immunology, Clinic of Gynecology and Obstetrics
1 School of Medicine - University of Belgrade (Yugoslavia)
Clin. Exp. Obstet. Gynecol. 1989, 16(1), 6–8;
Published: 10 March 1989
Abstract

The level of passive neonate protection against HSV depends on the transplacen-tally bodies’ transplacental passage in a group of women who delivered vaginally and pregnant women who had cesarean section, with the aim of examining the influence of the mode of delivery on the level of passive immuninty to HSV. Serologic examination was performed in a group of 102 women who delivered vaginally and 80 pregnant women who had cesarean section, using the test of microneutralization. The titer of anti HSV type 1 and anti HSV type 2 antibodies in the mother’s and cord blood was determined and compared. The cord serum neutralizing HSV type 1 antibodies’ titer, was twice higher as compared to those in mother’s blood in 60.7% of paired sera in the group of women who delivered vaginally. The cord serum anti HSV type 1 titers were twice as high as compared to those in mothers’ blood only in 15.5% of paired sera in group of pregnant women who had cesarean section. The results of this study point to the possibility that antibody transfer through the placenta is an active and selective process that depends also on the mode of delivery: there are lower levels of HSV neutralizing antibodies in the cord sera of infants whose mothers had cesarean section com-pared to those who delivered vaginally.
Keywords
Herpes simplex virus (HSV)
passive immunity
cesearean section
vaginal de-livery
neutralizing anti HSV antibodies
Share
Back to top